PTC-510 free base

• CAT Number: I035178
• CAS Number: 865531-74-4(TFA salt)
• Molecular Formula: C26H26BrN3O2S
• Molecular Weight: 524.48
• Purity: 98%
• Synonyms: PTC-510; PTC 510; PT-510; PTC-510 free base
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-bromo-13-cyclohexyl-10-(4-methoxyphenyl)-12-sulfanylidene-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),3,5-tetraen-14-one
• InChI: InChI=1S/C26H26BrN3O2S/c1-32-18-10-7-15(8-11-18)24-23-20(19-13-16(27)9-12-21(19)28-23)14-22-25(31)29(26(33)30(22)24)17-5-3-2-4-6-17/h7-13,17,22,24,28H,2-6,14H2,1H3
• InChIKey: WFMYUKAIOWLABZ-UHFFFAOYSA-N
• SMILES: COC1=CC=C(C=C1)C2C3=C(CC4N2C(=S)N(C4=O)C5CCCCC5)C6=C(N3)C=CC(=C6)Br

PTC-510 Free Base(CAT: I035178) is a novel inhibitor of hypoxia-induced vascular endothelial growth factor (VEGF) expression. By suppressing VEGF upregulation under hypoxic conditions, it plays a critical role in modulating angiogenesis and vascular remodeling. This makes it particularly significant in oncology research, where abnormal VEGF expression contributes to tumor growth and metastasis. PTC-510 Free Base offers a precise mechanism for studying hypoxia-driven VEGF pathways, providing a valuable tool for investigating therapeutic strategies targeting angiogenesis in cancer and other diseases involving aberrant vascular activity. Its efficacy positions it as a promising agent in advanced pharmacological studies.